2月24日，深圳华大智造科技股份有限公司公告披露，出售子公司100%股权及调整 CoolMPS 测序技术 《授权许可协议》。 深圳华大智造科技股份有限公司（以下简称"华大智造"或"公司"）全资子公司 MGI Tech R&D HONG KONG CO., LIMITED（以下简称"MGI R&D HK"）与 Swiss Rockets AG（以下简称"Swiss Rockets"）签署了《股份购买协议》，拟将 MGI R&D HK 剥离相关资产 及负债后的全资子公司Complete Genomics, Inc.（以下简称"CGI"）100%股权以约 5,000 万美元的对价出 售给 Swiss Rockets，最终交易价格以交割情况为准。 MGIUS LLC、CGI 与 Swiss Rockets 签署了《授权许可协议修正案》，拟在《CoolMPS 授权许可协议》 基础上，新增将公司的 StandardMPS 测序技术（以下简称"StandardMPS"）及通用测序技术有偿授权给 Swiss Rockets。在美国及加拿大区域内，Swiss Rockets 将获得 StandardMPS 测序技术相关的专利、 ...

Group 1: Resumption of Trading - Yongtai Technology has terminated the purchase of 25% equity in Yongtai High-tech from CATL, leading to the resumption of its stock trading [1] - Runze Technology plans to acquire 42.56% equity in Guangdong Runhui through a convertible bond issuance, further integrating IDC and AIDC business resources, resulting in stock resumption [1] Group 2: Capital Increase and Restructuring - Zongshen Power intends to swap its motorcycle engine business with Longxin General's general machinery business, which is expected to constitute a major asset restructuring [2] - Nanjing Chemical Fiber plans to acquire 100% equity in Nanjing Craft through asset swaps, share issuance, and cash payments [3] - Southwest Securities plans to raise no more than 6 billion yuan through a private placement [4] Group 3: Equity Transfer and Buyback - Hemai Co., Ltd. has a planned agreement to transfer 5.99% equity from Hainan Xinhai [5] - Luxshare Precision has conducted its first share buyback of 9.9 million shares, with a total transaction amount of nearly 500 million yuan [6] Group 4: External Investment and Daily Operations - Gaode Infrared has signed a contract for a complete equipment system worth 1.851 billion yuan, accounting for 69% of its audited revenue for 2024 [7] - Shenghong Technology now holds 100% equity in SPMY, with the target company becoming its FPC/PCB production base in Malaysia [7] - BGI Genomics plans to sell 100% equity in Complete Genomics for 50 million USD and adjust the licensing of CoolMPS sequencing technology [8] - Aolian Electronics' controlling shareholder, Ruiying Assets, has terminated the control transfer with Chaocheng Innovation [9] - Frontier Biotech has signed a licensing agreement with GlaxoSmithKline, receiving a 40 million USD upfront payment and 13 million USD in milestone payments [9] - Baili Tianheng's clinical trial for iza-bren (EGFR×HER3 dual antibody ADC) for locally advanced or metastatic triple-negative breast cancer has reached its primary endpoint in interim analysis [9] - Donghong Co., Ltd. has won a procurement project for pressure steel pipes and accessories worth 353 million yuan [10] - ST Xintong's subsidiary has signed a server procurement contract worth 400 million yuan [11] Group 5: Performance Changes - Yingshi Innovation expects a net profit of 964 million yuan in 2025, a year-on-year decrease of 3.08% [12]

Core Viewpoint - The company is planning to acquire 100% equity of Zhongshan Dehua Chip Technology Co., Ltd. through a combination of issuing shares and cash payment, while also raising matching funds, which is not expected to constitute a major asset restructuring [1] Group 1 - The company's stock will be suspended from trading starting January 13, 2026, for no more than 10 trading days [1] - The board of directors approved the transaction proposal on January 22, and trading will resume on January 23 [1] - The company received an inquiry letter from the Shanghai Stock Exchange on the same day and has responded and revised the proposal by February 6 [1] Group 2 - As of the announcement date, the audit and evaluation work related to the transaction is progressing smoothly [1] - The transaction is subject to multiple approvals, indicating a level of uncertainty [1]

Group 1: Transaction Progress - CNOOC Engineering (600583) announced on December 2025 that its subsidiary plans to acquire a 49% stake in China Offshore Fluor Heavy Industry Co., Ltd. from Fluor International Limited for 859 million RMB. Upon completion, CNOOC Engineering will achieve full ownership of China Offshore Fluor [1] Group 2: Performance and Operating Conditions - As of February 2026, the market expects Fluor's revenue for the fourth quarter of 2025 to decline year-on-year, but some institutions are focusing on its long-term profitability and potential improvement in earnings per share. The specific date for the announcement of Fluor's full-year 2025 results has not yet been disclosed [2] Group 3: Institutional Perspectives - Recent institutional ratings have remained stable. As of February 2026, among the 11 institutions covering Fluor, 55% have a buy or hold rating, while 45% have a hold rating, with no sell or downgrade ratings. The average target price set by institutions is $50.56 [3]

Group 1 - The core point of the article is that Qusleep Technology (301336) announced a share transfer agreement where its major shareholder, Suzhou Industrial Park Shunwei Technology Venture Capital Partnership, will transfer 2 million shares (5.00% of total shares) to Hangzhou Runxi Enterprise Management Consulting Partnership at a price of 54.946 yuan per share, totaling approximately 110 million yuan [1][2] - The transaction is expected to optimize Qusleep Technology's equity structure and improve governance efficiency, while also signaling potential collaboration in resource sharing, market expansion, and industrial synergy between the parties involved [1] - Qusleep Technology is an internet retail company focused on innovative home products related to sleep technology, and it is a strategic partner in the sleep sector within the Xiaomi ecosystem [2] Group 2 - The transfer will not affect the business cooperation between Qusleep Technology and the Xiaomi ecosystem, as stated by a company representative [2] - After the completion of the share transfer, Shunwei Investment and its concerted action party, Tianjin Jinmi, will still hold a combined 2.02% of Qusleep Technology's shares [2]

Core Viewpoint - The restructuring process of Singshan Group has reached a significant turning point with the signing of a restructuring investment agreement, leading to a surge in Singshan Co., Ltd.'s stock price and an increase in its market capitalization to 35.6 billion yuan [1][3]. Group 1: Restructuring Agreement Details - The controlling shareholder, Singshan Group Co., Ltd., and its wholly-owned subsidiary signed a restructuring investment agreement with Anhui Wanwei Group and Ningbo Financial Asset Management Co., Ltd. [3]. - Upon successful completion of the restructuring, the controlling shareholder will change to Wanwei Group, with the actual controller being the State-owned Assets Supervision and Administration Commission of Anhui Province [3]. - A consortium consisting of Wanwei Group, Anhui Conch Group, and Ningbo Jinzhi was selected as the winning bidder for the restructuring [3]. Group 2: Financial Terms of the Agreement - Wanwei Group will acquire a controlling interest in Singshan Co., Ltd. for a total consideration of no more than 7.156 billion yuan, controlling 21.88% of the voting rights [3][4]. - The direct acquisition involves a cash payment of 4.987 billion yuan for 13.50% of the shares, while the remaining 8.38% will be acquired through immediate and future funding arrangements [4]. - The immediate funding will be at a price of 11.50 yuan per share, with a structured payment plan and a 36-month lock-up period for the shares [4][5]. Group 3: Future Projections and Performance - Singshan Co., Ltd. anticipates achieving a net profit of 400 million to 600 million yuan in 2025, marking a turnaround from losses in 2024 [6]. - The expected growth is attributed to strong sales in core businesses, including negative electrode materials and polarizers, with a significant increase in profitability [6]. - The company is projected to maintain its position as the world's largest producer of artificial graphite negative materials in 2025 [6].

Core Viewpoint - Shanghai Pharmaceuticals announced the intention to publicly transfer 30% of its stake in China-U.S. Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd. (hereinafter referred to as "China-U.S. Bristol-Myers Squibb") through a property rights transaction, with a minimum listing price of 1.023 billion yuan [1][4]. Group 1: Company Overview - China-U.S. Bristol-Myers Squibb, established in 1982, is a well-known Sino-U.S. joint venture pharmaceutical company with a registered capital of 18.44 million USD. The shareholding structure includes Bristol-Myers Squibb (China) Investment Co., Ltd. holding 60%, Shanghai Pharmaceuticals holding 30%, and China National Pharmaceutical Group Asset Management Co., Ltd. holding 10% [2][5]. - The company has launched nearly 30 products in China, covering prescription drugs for cardiovascular, metabolic, and antibiotic treatments, as well as over-the-counter products like pain relievers and multivitamins [2][5]. Group 2: Financial Performance - In 2016, China-U.S. Bristol-Myers Squibb achieved a historical peak with revenues of 4.724 billion yuan and a net profit of 622 million yuan. However, the company's operational performance has declined since then [2][5]. - For the year 2024, the company reported revenues of 1.795 billion yuan and a net profit of 248 million yuan. In the first three quarters of 2025, revenues further declined to 1.096 billion yuan, with a net profit of only 87.11 million yuan [2][5][7]. Group 3: Share Transfer and Market Strategy - In September 2025, it was reported that Bristol-Myers Squibb signed an agreement to sell its 60% stake in China-U.S. Bristol-Myers Squibb to an affiliate of Hillhouse Capital. This move is aimed at allowing Bristol-Myers Squibb to focus on key growth areas while leveraging local manufacturing and market advantages [3][6]. - The transfer of 30% of the stake by Shanghai Pharmaceuticals indicates a potential comprehensive adjustment in the shareholding structure of this over 40-year-old joint venture pharmaceutical company. The minimum price for the stake transfer is set at 1.023192 billion yuan, reflecting a strategic decision to maximize asset value and protect the interests of all shareholders, especially minority shareholders [3][6].

Key Points - JinkoSolar has not reported any revenue from "space photovoltaic" orders [1] - Shuangliang Energy has not yet engaged in any space photovoltaic-related business [1] - CITIC Bank has increased its investment in CITIC Financial Leasing Co., Ltd. by 2 billion yuan [1] - Palm Holdings has won a bid for the construction project of high-standard farmland in Shuyang District, Shangqiu City for 2025 [1] - Shanghai Pharmaceuticals plans to transfer its 30% stake in Amgen [1] - Huanxu Electronics expects a net profit of 1.853 billion yuan for 2025, a year-on-year increase of 12.16% [1] - Changan Automobile plans to repurchase shares worth 1 billion to 2 billion yuan [1] - Jinpu Garden plans to reduce its shareholding by no more than 2% [1] - Sileck's subsidiary has received a project confirmation letter from a client [1] - Zhongwen Online intends to collaborate with Tencent on the authorization of animated micro-short dramas [1] Performance - Qilu Bank reported a net profit of 5.713 billion yuan for 2025, a year-on-year increase of 14.58% [2] - Guomai Heavy Industry achieved a net profit of 479 million yuan for 2025, a year-on-year increase of 10.89% [2] - Huanxu Electronics reported a net profit of 1.853 billion yuan for 2025, a year-on-year increase of 12.16% [2] Equity Acquisition - Shengxin Lithium Energy's subsidiary plans to acquire a 13.93% stake in Huirong Mining [2] - Hongchang Technology intends to acquire a 21% stake in Liangzhi Joint [2] - Shanghai Pharmaceuticals plans to transfer its 30% stake in Amgen [2] Share Buyback - Changan Automobile plans to repurchase shares worth 1 billion to 2 billion yuan [2] Shareholding Changes - Pulite's shareholder Zhou Wu plans to reduce his holdings by no more than 5.985 million shares [2] - Fuchuang Precision's shareholder Guotou Venture Capital plans to reduce its holdings by no more than 3% [2] - Changhong Huayi's directors and senior management plan to increase their holdings by no less than 3.3583 million yuan [2] - Jinpu Garden's shareholders plan to reduce their holdings by no more than 2% [2] - Kangst's shareholders plan to reduce their holdings by no more than 3.3799% [2] Other Developments - Sileck's subsidiary has received a project confirmation letter, with an expected total procurement of approximately 360 million cylindrical battery shells [2] - Zhongwen Online intends to collaborate with Tencent on the authorization of animated micro-short dramas [2]

Core Viewpoint - Shanghai Pharmaceuticals plans to transfer 30% equity stake in its subsidiary, China Medical Shanghai Bristol-Myers Squibb Pharmaceutical Co., Ltd. (referred to as "China Medical Bristol-Myers Squibb"), through a public listing with a minimum transfer price of 1.023 billion yuan [1][2] Group 1: Transaction Details - The transfer price is based on the previous equity disposal plan by Bristol-Myers Squibb, which aimed to sell its 60% stake in China Medical Bristol-Myers Squibb for approximately 480 million USD, equating to 1.44 billion USD for Shanghai Pharmaceuticals' 30% stake [1] - The transaction will result in Shanghai Pharmaceuticals no longer holding any equity in China Medical Bristol-Myers Squibb if completed successfully [1] Group 2: Company Financials - China Medical Bristol-Myers Squibb, established in 1982, has a registered capital of 18.44 million USD and operates in the pharmaceutical manufacturing sector [2] - For the fiscal year 2024 and the first three quarters of 2025, the company reported revenues of 1.795 billion yuan and 1.096 billion yuan, with net profits of 248 million yuan and 87.11 million yuan, respectively [2] - As of September 30, 2025, the total assets of China Medical Bristol-Myers Squibb amounted to 1.262 billion yuan, with net assets of 797 million yuan [2] Group 3: Strategic Implications - The transaction is expected to maximize asset value and protect the interests of all shareholders, particularly minority shareholders [1] - Shanghai Pharmaceuticals asserts that this transaction will not significantly impact its normal operations and financial status, while also optimizing its investment structure [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴該等內容 而引致之任何損失承擔任何責任。 ( 在中華人民共和國註冊成立的股份有限公司 ) (股份代碼: 01171) 內幕消息 關於掛牌轉讓全資子公司100%股權的公告 兗礦能源集團股份有限公司（「本公司」，連同其附屬公司，統稱「本集團」）根據香港聯合交易所 有限公司（「香港聯交所」）證券上市規則（「香港上市規則」）第13.09(2)條以及香港法例第571章證 券及期貨條例第XIVA部項下內幕消息條文（定義見香港上市規則條文）刊發本公告。 兗礦能源集團股份有限公司 YANKUANG ENERGY GROUP COMPANY LIMITED* 交易情況概述 本公司全資子公司兗礦能源（鄂爾多斯）有限公司在山東產權交易中心公開掛牌轉讓內蒙古鑫泰煤 炭有限公司（「鑫泰煤炭」）100%股權（「本次股權掛牌」），具體掛牌信息可通過山東產權交易中心 官網查詢，網址如下： （http://www.sdcqjy.com/proj/tc/9c4f1bfb4d5e4b ...